Symposium 7: Pharmacological algotuhm in diabetes mellitus type 2 without previous events

Diabetes in the world is growing by leaps and bounds, according to I.D.F. more than 450 million people suffer from Diabetes and the prognosis is not very promising. In Argentina the situation is no different where more than 12% of the population suffers from this disease, although half of them do not know their diagnosis. The current treatment guidelines for patients with type 2 diabetes, agreed upon by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), divide patients with this pathology into two groups: those with cardiovascular risk or established renal or cardiac disease and those without. In the until recently accepted concept, they were in turn subdivided into prioritization groups in those with a pressing need to avoid hypoglycemia, a second subgroup with a need to lose weight, and those in whom cost is a major problem. Recently an update was proposed according to new evidence in which a paradigm shift is proposed focusing only on two aspects: glucocentric and centrist weight. The focus of treatment is centered on behavioral approaches, medications and even metabolic surgery, always taking a holistic approach to the patient. Current evidence and new drugs that have an impact on weight reduction make targeting obesity a plausible goal. The prevalence of the overweight/obesity complex continues to grow and by 2030 it is expected that around 50% of the US population will be obese and 25% morbidly obese. In this context, drugs such as GLP-1 analogues have gained ground and have become the first line in this type of patients. They are often associated with other drugs such as SGLT2 inhibitors.